mantle cell lymphoma

[Cell Death & Disease] Investigators showed that ciclopirox (CPX) displayed strong anti-tumorigenic activity on glioblastoma multiforme (GBM). Mechanistically, CPX inhibited GBM cellular migration and invasion by reducing N-Cadherin, MMP9 and Snail expression.

[Blood Cancer Journal] Researchers assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed and relapsed/refractory B-cell non-Hodgkin lymphoma patients.

[British Journal of Haematology] Scientists demonstrated that the clinically approved iron chelator deferasirox exerts an anti‐tumoral effect in mantle cell lymphoma cell lines and patient cells.

[Nature Communications] Scientists integrated in situ Hi-C and nine additional omics layers. Beyond conventional active and inactive compartments, they uncovered a highly-dynamic intermediate compartment enriched in poised and polycomb-repressed chromatin.

[British Journal of Cancer] Investigators tested inhibitors of cap-dependent mRNA translation for the ability to sensitise diffuse large B-cell lymphoma and mantle cell lymphoma cells to apoptosis by venetoclax.

[Gilead Sciences, Inc.] Kite announced that the FDA has granted accelerated approval to Tecartus™, the first and only approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.